Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 412 of 5804
-
New drug tarlatamab targets Hard-to-Treat brain tumors
Disease control Recruiting nowThis is a phase 2 study to assess how useful study drug tarlatamab is for the treatment of patients with recurrent/refractory oligodendroglioma or astrocytoma with a mutation in the IDH gene.
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 26, 2026 19:02 UTC
-
New hope for stomach cancer: experimental combo enters final trial phase
Disease control Recruiting nowThis study aims to evaluate the efficacy and safety of SHR-A1811 combined with chemotherapy and immune checkpoint inhibitor versus standard first-line therapy in gastric or gastroesophageal junction adenocarcinoma.
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Engineered immune cells take aim at stubborn leukemia after transplant
Disease control Recruiting nowTo observe the efficacy and safety of CD7-targeted chimeric antigen receptor T cells in the treatment of T-lymphoblastic leukaemia/lymphoma with postive measurable residual disease positive post allogeneic stem cell transplantation
Phase: PHASE1 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Gene therapy trial targets Parkinson's at its genetic root
Disease control TerminatedThe goal of this clinical trial is to learn about the safety of CAP-003 gene therapy in adults with GBA1 associated Parkinson's Disease. It will also provide information about whether CAP-003 demonstrates efficacy in these adults. Participants will have a single intravenous infu…
Phase: PHASE1, PHASE2 • Sponsor: Capsida Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug rilzabrutinib aims to tame rare blood disorder
Disease control Recruiting nowThis is a parallel-group, Phase 3, double-blind, 2-arm study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb response (DHR) compared with placebo in approximately 90 male and female participants ≥ 18 years of age with a confirmed diagn…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New scan could spot prostate cancer more accurately
Diagnosis Recruiting nowThis is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prostate cancer (PCa).
Phase: PHASE3 • Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
New hope for lung cancer patients with stubborn mutation
Disease control Recruiting nowThis is a Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with First-Line Osimertinib Treatment and whose Tumors harbor a C797S mutation within the Epidermal…
Phase: PHASE2 • Sponsor: Wayshine Biopharm, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:42 UTC
-
New drug combo shows promise in tough pancreatic cancer
Disease control OngoingThis study is testing narmafotinib, a type of drug called a focal adhesion kinase (FAK) inhibitor, when it is given in combination with 4 chemotherapy drugs in a regimen called FOLFIRINOX, to patients who have pancreatic cancer which has metastasised (spread). The study is being …
Phase: PHASE1, PHASE2 • Sponsor: Amplia Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New CAR T-Cell therapy takes on rare blood disease
Disease control Recruiting nowOpen-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.
Phase: PHASE1, PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Brain zaps for schizophrenia? new trial tests deep brain stimulation
Disease control Recruiting nowThis is a prospective, randomized, interventional study designed to evaluate the efficacy and safety of SEEG-guided deep brain stimulation (DBS) for symptom improvement in patients with treatment-resistant schizophrenia. Using stereo-electroencephalography (SEEG) to record brain …
Phase: NA • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Eye test and blood markers could spot dangerous pregnancy condition earlier
Diagnosis CompletedHypertensive disorders of pregnancy (HPT) are an important cause of maternal-feto-neonatal morbidity and mortality, being one of the three leading causes of maternal death in our country and in developing countries. The only cure for THE is termination of pregnancy, which ends up…
Phase: NA • Sponsor: Saint Thomas Hospital, Panama • Aim: Diagnosis
Last updated Jul 18, 2026 00:00 UTC
-
New drug combo aims to boost stroke recovery
Disease control Recruiting nowThis randomized controlled trial aims to evaluate whether adjunctive tirofiban therapy combined with endovascular treatment (EVT) improves neurological outcomes in patients with acute large vessel occlusion due to large-artery atherosclerosis. Patients will be randomized to recei…
Phase: NA • Sponsor: Beijing Anzhen Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New shot could tame hay fever symptoms for good
Symptom relief Recruiting nowAllergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion,…
Phase: PHASE3 • Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 26, 2026 13:41 UTC
-
New pill aims to quiet Alzheimer's psychosis
Symptom relief Recruiting nowML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP). The primar…
Phase: PHASE2 • Sponsor: MapLight Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Can a phone app help prevent heart attacks? new study aims to find out
Disease control Recruiting nowDespite the availability of medications, many people around the world continue to live with long-term health problems like heart disease, stroke and diabetes. In Canada, heart disease is a leading cause of death. Managing these health issues can be done by changing diet and lifes…
Phase: NA • Sponsor: University of Toronto • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Could chemo before surgery beat cancer better?
Disease control OngoingThis clinical trial aims to compare the effectiveness and safety of two treatment options for patients with high-risk upper tract urothelial carcinoma (UTUC). One group will receive neoadjuvant chemotherapy with gemcitabine and cisplatin followed by surgery (radical nephrouretere…
Phase: PHASE2 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could an arthritis drug boost IVF success in endometriosis patients?
Disease control OngoingThis prospective study targets infertile women with endometriosis (EM) who have experienced a previously failed Intracytoplasmic Sperm Injection (ICSI) trial. Using the P-I-C-O framework, the study evaluates whether the administration of an anti-TNF-α therapy (Intervention) 4-5 d…
Phase: PHASE2 • Sponsor: Benha University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New Pill-and-Shot combo aims to wipe out HER2+ breast cancer before surgery
Disease control Recruiting nowThe goal of this clinical trial is to evaluate the efficacy and safety of oral paclitaxel plus fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in the neoadjuvant treatment of HER2+ breast cancer patients.
Phase: NA • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Smartphone rehab for heart failure: a new hope for rural patients?
Disease control Recruiting nowThis study evaluates a mobile health (mHealth) home-based cardiac rehabilitation program for patients with heart failure. We will stratify randomization between rural and urban populations, with the goal to assess implementation of cardiac rehabilitation across these two geograph…
Phase: PHASE3 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a common food fiber boost immunotherapy in kidney cancer?
Disease control Recruiting nowThis phase I/II trial tests the safety and effectiveness of inulin gel in combination with ipilimumab and nivolumab in treating patients with kidney cell cancer (renal cell carcinoma \[RCC\]) that has spread from where it first started (primary site) to other places in the body (…
Phase: PHASE1, PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 14:41 UTC